Picture EBD Group BioPharm America 2021 Digital BPA2021 650x80
Document › Details

c-LEcta GmbH. (5/24/18). "Press Release: c-LEcta Reports Financial Results of Business Year 2017".

Organisation Organisation c-LEcta GmbH
Products Product industrial enzyme
  Product 2 industrial biotechnology
Person Person Fietz, Carsten (c-LEcta GmbH 201509– Head Finance + Administration before CFO)

The Leipzig-based industrial biotechnology company has recently closed its financial accounts for last year with very positive outcomes. The company is following a product-driven growth path by investing into future product businesses and could nonetheless close the business year 2017 with profit on earnings. The total revenues increased by about 45% mainly caused by a strong increase in product revenues of around 185%. This indicates that the transformation into a product company is on a very good way.

c-LEcta generates positive operational results already since 2014, whereas 2017 was the most successful year in its history. In both businesses, the strategic industrial partnerships as well as the product sales, c-LEcta achieved significantly increased revenues, underlying the continuous growth of the company.

“The final results exceed the forecasts in revenues and also in EBIT. Especially the growth of product sales contributed to this pleasant development confirming our product driven growth strategy” comments Carsten Fietz, Head of Finance and Administration.

Record changed: 2019-01-13


Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for c-LEcta GmbH

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2021 NYC A October 650x80px

» top